DEFB126: A Potential Drug Target for Neurodegenerative Diseases

Target Name: DEFB126

NCBI ID: G81623

DEFB126

DEFB126: A Potential Drug Target for Neurodegenerative Diseases

DEFB126 (C20orf8) is a protein that is expressed in various tissues throughout the body. It is a member of the cryptic CCRN-type family and is characterized by its unique expression in the central nervous system (CNS) and its role in the development and progression of neurodegenerative diseases.

Recent studies have identified DEFB126 as a potential drug target for a variety of neurological conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Its unique expression in the CNS and its involvement in the development of neurodegenerative diseases make it an attractive target for drug development.

One of the key mechanisms by which DEFB126 contributes to neurodegenerative diseases is its role in the regulation of synaptic plasticity. Synaptic plasticity is the ability of the brain to change and adapt over time, and it is a crucial factor in the development and progression of neurodegenerative diseases.

DEFB126 has been shown to play a role in the regulation of synaptic plasticity by promoting the production of a protein called NG2. NG2 is a key regulator of synaptic plasticity and has been shown to contribute to the development of neurodegenerative diseases.

In addition to its role in synaptic plasticity, DEFB126 has also been shown to contribute to the development and progression of neurodegenerative diseases by promoting the production of another protein called Tau. Tau is a protein that is involved in the regulation of cell division and has been shown to contribute to the development of neurodegenerative diseases.

The identification of DEFB126 as a potential drug target has led to a significant increase in research on its role in neurodegenerative diseases. Further studies are needed to better understand its mechanisms of action and to identify potential drug targets.

In conclusion, DEFB126 is a protein that has been identified as a potential drug target for a variety of neurological conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Its unique expression in the CNS and its role in the regulation of synaptic plasticity and the development and progression of neurodegenerative diseases make it an attractive target for drug development. Further studies are needed to better understand its mechanisms of action and to identify potential drug targets.

Protein Name: Defensin Beta 126

Functions: Highly glycosylated atypical beta-defensin involved in several aspects of sperm function. Facilitates sperm transport in the female reproductive tract and contributes to sperm protection against immunodetection; both functions are probably implicating the negative surface charge provided by its O-linked oligosaccharides in the sperm glycocalyx. Involved in binding of sperm to oviductal epithelial cells to form a sperm reservoir until ovulation. Release from the sperm surface during capacitation and ovaluation by an elevation of oviductal fluid pH is unmasking other surface components and allows sperm to penetrate the cumulus matrix and bind to the zona pellucida of the oocyte (By similarity). In vitro has antimicrobial activity and may inhibit LPS-mediated inflammation (PubMed:19373462, PubMed:23229569)

The "DEFB126 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB126 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets